IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

KKR buys stake in Indian firm Gland Pharma for $200 million

8:44 AM MST | December 2, 2013 | Natasha Alperowicz

KKR, a leading global investment firm, says it will acquire a minority stake in Gland Pharma (Hyderabad, India), a leading Indian pure-play generic injectables pharmaceutical products company focusing mainly on the US market. KKR will pay approximately $200 million for the entire stake held by Evolvence India Life Sciences Fund, an existing private equity investor in Gland. The transaction, which will give KKR approximately 35% in Gland, is subject to regulatory approvals and other customary closing conditions.    Gland, established in 1978, develops...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa